Advancing Psychedelic PTSD Therapy
Clearmind and NeuroThera Advance Patent for MDMA-PEA PTSD Therapy Program
Key Points
Clearmind’s IP portfolio includes 19 patent families and 32 granted patents globally, underscoring broader protection beyond the MDMA-PEA program.
The FDA finalized its psychedelic drug development guidance on July 13, 2026, explicitly including MDMA and outlining considerations for clinical investigations (trial design, data collection, patient safety and NDA requirements).
The U.S. patent application for the MDMA-PEA combination has been published by the USPTO, marking a US-facing intellectual property milestone within the NeuroThera-Clearmind collaboration.
Clearmind’s broader IP landscape includes non-hallucinogenic, psychedelic-derived neuroplastogens, indicating diversification across neuropsychiatric, metabolic and addiction-disorder programs.
Clearmind Medicine and NeuroThera Labs have secured a major intellectual property milestone with the US patent publication for their MDMA-PEA combination therapy targeting PTSD, anxiety, and eating disorders MarketScreener. The collaboration aims to combine MDMA with N-acylethanolamines (PEA) to potentially boost the drug's potency, widen the therapeutic window, and reduce side effects and required dosing.
The development arrives as the FDA finalized its first-ever guidance on psychedelic drug development on July 13, 2026 TipRanks, explicitly including MDMA and outlining requirements for clinical trials, data collection, and patient safety. The regulatory green light signals growing federal acceptance of psychedelic medicines and could reshape how future MDMA-based treatments move through the approval pipeline.
The Science Behind Combining MDMA With PEA
MDMA, also known as ecstasy, has long shown promise for treating trauma-related disorders. PEA is a naturally occurring compound in the body that researchers believe could amplify MDMA's therapeutic effects NASDAQ. By pairing the two molecules, the collaboration aims to achieve stronger results while using smaller doses. This could mean fewer side effects and a safer overall treatment experience for patients.
A Growing Patent Portfolio Across Multiple Programs
Clearmind's intellectual property reach extends far beyond the MDMA-PEA combination. The company maintains 19 patent families with 32 granted patents globally, according to MarketScreener, protecting its broader pipeline. The company is also developing non-hallucinogenic, psychedelic-derived neuroplastogens for neuropsychiatric, metabolic, and addiction disorders, diversifying its bets across multiple therapeutic areas and disease targets.
FDA's New Roadmap for Psychedelic Medicine Development
The FDA's finalized guidance, released on July 13, 2026, represents the first regulatory framework specifically designed for psychedelic drugs TipRanks. The agency outlined explicit considerations for clinical trial design, data collection methods, patient safety protocols, and new drug application (NDA) requirements. This clarity removes uncertainty for companies like Clearmind and creates a standardized path forward for MDMA-based and other psychedelic therapies seeking approval.
Thirteen Patent Applications Build the Global IP Fortress
The NeuroThera-Clearmind collaboration has generated thirteen patent applications worldwide, building a protective moat around the MDMA-PEA technology MarketScreener. The US patent publication marks a critical milestone in securing North American intellectual property rights. This expanding portfolio suggests the companies expect the therapy to move toward clinical trials and eventual commercialization, with strong legal protection in place to defend their competitive advantage globally.
Sentiment
Mostly PositivePublishers
11
Articles
40
Reach
51
